supplementNot FDA-approvedOTC supplementSold in the US as an unregulated dietary supplement; the Cochrane review found the certainty of evidence for claudication outcomes to be low to very low
Propionyl-L-CarnitineBenefits, Dosage & Interactions
Also known as: PLC
Propionyl-L-Carnitine (PLC) is a naturally occurring derivative of L-carnitine, an amino acid-like compound crucial for energy production within cells. Unlike L-carnitine, which primarily transports long-chain fatty acids into mitochondria for beta-oxidation, PLC enters the mitochondrial matrix directly. Research on Propionyl-L-Carnitine focuses on endurance and heart and circulatory health.
How much Propionyl-L-Carnitine do people take?
Cited trials used oral propionyl-L-carnitine doses of roughly 1–2 g/day for intermittent claudication and 1 g twice daily (2 g/day) in the Peyronie's disease trial. Route reported: Oral, as tablets in the cited trials. Frequency reported: Divided doses, typically twice daily. These are amounts documented in the cited studies and labels for Propionyl-L-Carnitine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 2 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials published.
Plasma half-life
Not applicable
Typical timing
in the morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Propionyl-L-Carnitine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Propionyl-L-Carnitine entry is written from. Each number matches an inline marker above.
- [1]Propionyl-L-carnitine for intermittent claudicationKamoen V, Vander Stichele R, Campens L, De Bacquer D, Van Bortel L, de Backer TL · The Cochrane Database of Systematic Reviews · 2021 · Peer-reviewed · PMID 34954832
- [2]Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter studyBrevetti G, Perna S, Sabbá C, Martone VD, Condorelli M · Journal of the American College of Cardiology · 1995 · Peer-reviewed · PMID 7594063
- [3]Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized studySafarinejad MR, Hosseini SY, Kolahi AA · The Journal of Urology · 2007 · Peer-reviewed · PMID 17706714
References & Evidence
Sources on this page that document Propionyl-L-Carnitine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Propionyl-L-Carnitine studied for?
What is Propionyl-L-Carnitine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Propionyl-L-Carnitine (PLC) is a naturally occurring derivative of L-carnitine, an amino acid-like compound crucial for energy production within cells. Unlike L-carnitine, which primarily transports long-chain fatty acids into mitochondria for beta-oxidation, PLC enters the mitochondrial matrix directly. Once inside, it is believed to contribute its propionyl group to coenzyme A, forming propionyl-CoA. This propionyl-CoA can then enter the tricarboxylic acid (TCA) cycle, an essential pathway for generating ATP, the cell's primary energy currency (PubChem).
PLC is found in various animal products and can also be synthesized in the body from L-carnitine. It has been investigated for its potential roles beyond general energy metabolism, particularly in areas related to cardiovascular health and exercise performance. Its unique metabolic pathway, involving the propionyl group, distinguishes it from L-carnitine and other carnitine derivatives like acetyl-L-carnitine (ALCAR), which contributes an acetyl group. Researchers are exploring how these distinct metabolic fates might translate into specific physiological effects and therapeutic applications (Examine.com).
What does the research say about Propionyl-L-Carnitine?
Tap a section to expand.
Propionyl-L-Carnitine (PLC) functions as a precursor to propionyl-CoA, an intermediate metabolite in the TCA cycle. Upon entering the cell and then the mitochondrion, the propionyl group is transferred from PLC to coenzyme A, yielding propionyl-CoA. This compound can then be converted to succinyl-CoA, which directly feeds into the TCA cycle, thereby potentially enhancing cellular energy production, particularly under conditions of stress or oxygen deprivation (PubChem).
Beyond its role in energy metabolism, PLC is thought to influence nitric oxide (NO) production. Some research suggests that PLC might enhance the activity of endothelial nitric oxide synthase (eNOS), an enzyme responsible for generating NO. Nitric oxide is a critical signaling molecule involved in vasodilation, which improves blood flow to tissues. By promoting vasodilation, PLC could potentially support cardiovascular function and improve oxygen delivery to muscles, which is relevant for endurance activities (Examine.com). Additionally, PLC may exhibit antioxidant properties, helping to mitigate oxidative stress, though this mechanism is considered secondary to its primary roles in energy and vasodilation (Cochrane Review).
Source for this section: Sources for How does Propionyl-L-Carnitine work?: Jumps to this entry in the sources and references list at the end of the page.
Propionyl-L-Carnitine (PLC) has been studied for several potential benefits, primarily related to cardiovascular health and exercise performance.
* **Cardiovascular Support:** Research suggests that PLC may improve exercise capacity in individuals with certain cardiovascular conditions, such as peripheral artery disease (PAD) and chronic heart failure. Studies have indicated that PLC can enhance walking distance and reduce symptoms like claudication (leg pain during exercise) in PAD patients. This effect is often attributed to improved energy metabolism within ischemic tissues and enhanced vasodilation (Cochrane Review, Mayo Clinic).
* **L-Carnitine Deficiency:** As a readily available carnitine precursor, PLC can help replete L-carnitine stores, particularly in cases of primary or secondary carnitine deficiency. It supports the overall carnitine pool, which is essential for fatty acid transport and energy production in various tissues (NIH ODS).
* **Exercise Performance (Endurance):** For healthy individuals, the evidence for significant improvements in endurance exercise performance is mixed. Some studies in specific populations or under certain conditions have noted potential benefits in reducing muscle fatigue and improving oxygen utilization during prolonged exertion. However, robust evidence demonstrating widespread performance enhancement in general athletic populations is still developing (Examine.com).
* **Erectile Dysfunction:** Limited research has explored PLC, often in combination with L-arginine, as a potential aid for improving erectile function, particularly in men with vascular origins for their erectile dysfunction. The proposed mechanism involves enhanced nitric oxide availability and improved blood flow (MedlinePlus).
It is important to note that while some benefits show promise, many are still under active investigation, and individual responses can vary.
Evidence for Propionyl-L-Carnitine (PLC) stems from various clinical trials and observational studies. For cardiovascular conditions, particularly peripheral artery disease (PAD), several randomized controlled trials and meta-analyses have investigated PLC. A Cochrane review analyzed studies on PLC for intermittent claudication in PAD, finding that it may improve maximum walking distance and pain-free walking distance. However, the review also highlighted variability in study design and outcomes, suggesting a need for more standardized research (Cochrane Review).
In the context of chronic heart failure, some studies have explored PLC's potential to improve cardiac function and exercise tolerance. While some positive effects have been reported, particularly in reducing symptoms and improving exercise capacity, these findings are not universally consistent across all studies. More large-scale, long-term trials are needed to fully elucidate its role in managing heart failure (Mayo Clinic).
Regarding exercise performance in healthy individuals, the scientific literature presents a mixed picture. Some smaller studies have suggested that PLC might reduce markers of muscle damage or improve perceived exertion during exercise, particularly in specific training regimens or unconditioned individuals. However, many larger reviews and meta-analyses conclude that definitive, widespread ergogenic benefits in well-trained athletes are not consistently supported by high-quality evidence (Examine.com).
For erectile dysfunction, studies often involve PLC in combination with other agents like L-arginine. While some studies have shown improvements in erectile function scores, particularly in comparison to placebo or other monotherapies, these findings typically come from smaller trials. Further independent and larger-scale research is needed to confirm these effects and understand the precise mechanisms contributing to any observed benefits (MedlinePlus). Overall, while promising in certain contexts, particularly cardiovascular health, the evidence base for all proposed benefits continues to evolve.
Propionyl-L-Carnitine (PLC) is generally considered well-tolerated when used at commonly studied dosages. Side effects, when they occur, are typically mild and transient.
* **Gastrointestinal Issues:** The most frequently reported side effects include digestive disturbances such as nausea, abdominal cramps, diarrhea, and indigestion (NIH ODS). These are often dose-dependent and can sometimes be mitigated by taking PLC with food or by reducing the dosage.
* **Body Odor:** Less commonly, some individuals may experience a 'fishy' body odor. This is thought to be due to an increase in trimethylamine, a metabolic byproduct, though it is more frequently associated with higher doses of L-carnitine itself (MedlinePlus).
* **Headache:** Rarely, headaches have been reported (Examine.com).
These side effects are typically not severe enough to warrant discontinuation of the supplement for most users. If any persistent or concerning side effects occur, it is advisable to consult a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While generally safe for most healthy adults, certain warnings and precautions should be considered before using Propionyl-L-Carnitine (PLC).
* **Kidney Disease:** Individuals with severe kidney disease, especially those undergoing dialysis, should use carnitine supplements, including PLC, with caution and only under strict medical supervision (Mayo Clinic). Accumulation of carnitine metabolites can occur in this population, potentially leading to adverse effects.
* **Seizure Disorders:** There have been isolated case reports suggesting that carnitine supplementation might increase seizure frequency in individuals with pre-existing seizure disorders or genetic predispositions. Therefore, caution is advised, and use should be monitored by a neurologist (DrugBank).
* **Hypothyroidism:** L-carnitine, and by extension its derivatives, theoretically could interact with thyroid hormones. Individuals with underactive thyroid (hypothyroidism) should consult their physician before using PLC, as it might potentially interfere with thyroid hormone action or medication (NIH ODS).
* **Pregnancy and Breastfeeding:** There is insufficient reliable information about the safety of using PLC during pregnancy or breastfeeding. As a precautionary measure, it is generally advised to avoid use unless specifically recommended and monitored by a healthcare provider (MedlinePlus).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Currently, there are no absolute contraindications for Propionyl-L-Carnitine (PLC) in healthy individuals when used at commonly studied dosages. However, as noted in the warnings section, extreme caution and medical supervision are strongly advised for:
* Individuals with severe kidney impairment, particularly those on hemodialysis, due to potential accumulation of metabolites.
* Individuals with a history of seizure disorders, as carnitine supplements might rarely exacerbate seizures.
These conditions are not typically considered absolute contraindications if the potential benefits outweigh the risks and competent medical oversight is in place. However, without such oversight, uncontrolled use in these populations could pose significant risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Propionyl-L-Carnitine (PLC) is generally considered to have a low risk of significant drug interactions. However, a few potential interactions warrant consideration:
* **Acenocoumarol and Warfarin (Anticoagulants):** There have been isolated reports suggesting that carnitine derivatives, including PLC, might potentially enhance the effects of anticoagulant medications like acenocoumarol and warfarin, leading to an increased risk of bleeding. While the evidence is limited, individuals taking these types of blood thinners should be monitored closely by their clinician if using PLC (DrugBank, MedlinePlus).
* **Thyroid Hormones:** As mentioned in warnings, there's a theoretical concern that carnitine derivatives might interfere with the action of thyroid hormones. Individuals undergoing thyroid hormone replacement therapy should discuss PLC use with their doctor, as dosage adjustments of thyroid medication might be necessary (NIH ODS).
* **HIV medications (Nucleoside Reverse Transcriptase Inhibitors - NRTIs):** Some NRTIs, such as zidovudine, can alter carnitine metabolism. While a clear interaction with PLC specifically is not definitively established, caution is advised, and medical consultation is recommended for individuals taking these medications (PubChem).
Always inform your healthcare provider about all supplements and medications you are taking to ensure safe co-administration. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Propionyl-L-Carnitine (PLC) is commonly taken in the morning. For studies investigating its effects on exercise performance or cardiovascular conditions, it is often administered once or twice daily. The absorption of PLC is generally not significantly impacted by food, allowing for flexibility in its intake, either with or without meals (Examine.com). Some individuals prefer taking it with food to minimize any potential gastrointestinal discomfort. Given its moderate half-life of approximately 4 hours, splitting a daily intake into two doses can help maintain more consistent plasma levels, though for once-daily dosing, morning intake is a common practice to align with daytime activities and energy needs (NIH ODS). Individual needs vary — talk to a licensed clinician.
Source for this section: Sources for When should you take Propionyl-L-Carnitine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Propionyl-L-Carnitine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Propionyl-L-Carnitine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
Frequently asked questions about Propionyl-L-Carnitine
Propionyl-L-Carnitine (PLC) is a derivative of L-carnitine, an amino acid-like compound. It plays a role in cellular energy production, particularly by contributing a propionyl group to the TCA cycle, and is also studied for its potential effects on blood flow and cardiovascular health (PubChem).
While all are carnitine derivatives, they have distinct functions. L-carnitine primarily transports fatty acids for energy. Acetyl-L-carnitine (ALCAR) is known for its role in supporting brain health and contributing an acetyl group to the TCA cycle. PLC contributes a propionyl group to the TCA cycle and is particularly noted for its potential impact on cardiovascular health and nitric oxide production (Examine.com).
PLC is generally considered safe for most healthy adults at commonly studied dosages. Mild gastrointestinal issues are the most common side effects. However, individuals with kidney disease, seizure disorders, or hypothyroidism should consult a clinician before use (NIH ODS).
The time frame for experiencing effects from PLC can vary depending on the individual, the condition being addressed, and the dosage. For conditions like peripheral artery disease, studies often involve several weeks or months of consistent supplementation before significant improvements in walking distance are observed (Cochrane Review). For general energy or exercise support, effects may be more subtle and less immediately noticeable.
Infrequently, some individuals might experience a 'fishy' body odor while taking carnitine supplements, including PLC. This is usually due to increased levels of trimethylamine and is more often associated with higher doses or certain metabolic predispositions (MedlinePlus).
Interaction risk for Propionyl-L-Carnitine comes from the rest of the stack: other supplements, prescription medicines, hormone therapy and peptides. Because Propionyl-L-Carnitine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Propionyl-L-Carnitine with no sign-up.
Propionyl-L-Carnitine is typically taken in the morning. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Propionyl-L-Carnitine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Propionyl-L-Carnitine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Propionyl-L-Carnitine varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Propionyl-L-Carnitine depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Propionyl-L-Carnitine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Cited trials used oral propionyl-L-carnitine doses of roughly 1–2 g/day for intermittent claudication and 1 g twice daily (2 g/day) in the Peyronie's disease trial. Route reported: Oral, as tablets in the cited trials. Frequency reported: Divided doses, typically twice daily. These are amounts documented in the cited studies and labels for Propionyl-L-Carnitine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Propionyl-L-Carnitine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Propionyl-L-carnitine(opens PubMed in a new tab)Drugs Aging · 1998 · PMID 9534023 · https://pubmed.ncbi.nlm.nih.gov/9534023/
- 2.Propionyl-L-carnitine for intermittent claudication(opens PubMed in a new tab)Cochrane Database Syst Rev · 2021 · PMID 34954832 · https://pubmed.ncbi.nlm.nih.gov/34954832/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 188824(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/188824
Verify at
Publisher search links for Propionyl-L-Carnitine. These are places to check the information — they are not citations, so they are not numbered.
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Propionyl-L-Carnitine?
Plain-text summary, safe to quote verbatim:
Propionyl-L-Carnitine (PLC) is a naturally occurring derivative of L-carnitine, an amino acid-like compound crucial for energy production within cells. Unlike L-carnitine, which primarily transports long-chain fatty acids into mitochondria for beta-oxidation, PLC enters the mitochondrial matrix directly. Research on Propionyl-L-Carnitine focuses on endurance and heart and circulatory health.
Source: DoseRoutine — https://doseroutine.com/library/propionyl-l-carnitine
Propionyl-L-Carnitine cheat sheet
DoseRoutine cheat sheet · Supplement
Propionyl-L-Carnitine
Propionyl-L-Carnitine (PLC) is a naturally occurring derivative of L-carnitine, an amino acid-like compound crucial for energy production within cells. Unlike L-carnitine, which primarily transports long-chain fatty acids into mitochondria for beta-oxidation, PLC enters the mitochondrial matrix directly.
Evidence
Strong
2 human randomized trials published.
Studied range
Cited trials used oral propionyl-L-carnitine doses of roughly 1–2 g/day for intermittent claudication and 1 g twice daily (2 g/day) in the Peyronie's disease trial
Route
Oral, as tablets in the cited trials
Frequency studied
Divided doses, typically twice daily
Timing
in the morning
Not FDA-approvedOTC supplementSold in the US as an unregulated dietary supplement; the Cochrane review found the certainty of evidence for claudication outcomes to be low to very lowEnduranceCardiovascular
Key references
- Propionyl-L-carnitine for intermittent claudication (2021)
- Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study (1995)
- Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study (2007)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/propionyl-l-carnitine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Propionyl-L-Carnitine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/propionyl-l-carnitine
What compounds are similar to Propionyl-L-Carnitine?
Others in the supplement category or studied for the same goals.
Which goals is Propionyl-L-Carnitine used for?
Other compounds studied for the same benefits as Propionyl-L-Carnitine.
Continue exploring
See every compound DoseRoutine catalogs for these goals.